Skip to main content

Table 1 Patient demographics and clinical characteristics of AS patients on different stages of hip involvement

From: The correlation between volumetric bone mineral density and morphological parameters of the proximal femur and clinical outcomes in ankylosing spondylitis patients with hip involvement

Characteristics

Total AS patients (n = 65)

Group A (n = 39)

Group B (n = 26)

P value

BMI

25.8 ± 4.7 (16.6–39.5)

25.9 ± 4.5 (17.7–38.9)

25.6 ± 5.0 (16.6–39.5)

0.851

Male gender, n (%)

56 (86.2%)

34 (87.2%)

22 (84.6%)

1.000

Age at onset (years)

23.3 ± 6.0 (14–39)

25.0 ± 5.9 (15–39)

20.9 ± 5.5 (14–34)

0.006

Age at outpatient visit (years)

33.3 ± 9.1 (17–54)

32.7 ± 7.5 (18–49)

34.2 ± 11.1 (17–54)

0.995

Duration of AS (years)

10.2 ± 9.4 (0–37)

8.0 ± 6.6 (0–24)

13.6 ± 11.8 (0–37)

0.131

Diagnosis delay (years)

5.6 ± 7.3 (0–33)

4.6 ± 6.2 (0–33)

7.1 ± 8.5 (0–27)

0.556

EAMs, n (%)

 Uveitis

4 (6.2%)

2 (5.1%)

2 (7.7%)

1000

 IBD

4 (6.2%)

2 (5.1%)

2 (7.7%)

1.000

 Family history, n (%)

14 (21.5%)

8 (20.5%)

6 (23.1%)

0.805

 HLA-B27 positivity, n (%)

61 (93.8%)

37 (94.9%)

24 (92.3%)

1.000

 Current use of NSAIDs, n (%)

43 (66.2%)

28 (71.8%)

15 (57.7%)

0.239

 Current use of DMARDs, n (%)

35 (53.8%)

24 (61.5%)

11 (42.3%)

0.128

 ESR (mm)

31.8 ± 20.3 (2–93)

27.9 ± 20.1 (2–91)

37.7 ± 19.6 (10–93)

0.020

 CRP (mg/L)

26.8 ± 27.1 (1.9–133.0)

22.8 ± 26.6 (1.9–133.0)

32.7 ± 27.1 (2.2–107.0)

0.035

 hsCRP (mg/L)

25.5 ± 28.7 (0.1–137.4)

22.3 ± 27.7 (0.1–131.5)

30.4 ± 30.0 (0.8–137.4)

0.111

 BASDAI

3.8 ± 2.1 (0.4–8.4)

3.0 ± 1.9 (0.4–7.8)

4.8 ± 1.9 (0.4–8.4)

0.001

 BASFI

2.1 ± 1.6 (0.2–6.3)

1.5 ± 1.0 (0.2–4.4)

3.2 ± 1.7 (0.5–6.3)

< 0.001

 SF-12 PCS

37.5 ± 12.0 (16.5–58.4)

40.5 ± 11.8 (19.6–58.4)

33.1 ± 11.1 (16.5–55.1)

0.014

 SF-12 MCS

39.3 ± 11.6 (17.1–57.8)

42.4 ± 11.3 (22.4–57.8)

34.9 ± 10.8 (17.1–54.3)

0.009

 ASQOL

6.4 ± 4.5 (0–17)

5.0 ± 4.1 (0–14)

8.4 ± 4.3 (2–17)

0.002

 HHS

75.7 ± 19.8 (24–100)

87.5 ± 9.6 (65–100)

58.1 ± 18.1 (24–95)

< 0.001

 BASRI-Hip

1.9 ± 1.4 (0–4)

0.9 ± 0.8 (0–2)

3.3 ± 0.5 (3–4)

< 0.001

  1. Group A represents the hips with absent, minimal or mild radiographic involvement (BASRI-Hip score = 0 or 1 or 2) and Group B represents the hips with moderate to severe radiographic involvement (BASRI-Hip score = 3 or 4)
  2. The value of continuous variables was presented as mean ± standard deviation and the categorical variables were based on presented as number plus percentage
  3. Abbreviations: AS Ankylosing spondylitis, BMI Body mass index, EAMs Extra-articular manifestations, IBD Inflammatory bowel disease, NSAIDs Nonsteroidal anti-inflammatory drugs, DMARDs Disease modifying anti-rheumatic drugs, ESR Erythrocyte sedimentation rate, CRP C reactive protein, hsCRP High sensitive C reactive protein, BASDAI Bath ankylosing spondylitis disease activity index, BASFI Bath ankylosing spondylitis functional index, SF-12 PCS short form-12 physical component summary, SF-12 MCS Short form-12 mental component summary, ASQOL Ankylosing spondylitis quality of life, HHS Harris hip score, BASRI-Hip The bath ankylosing spondylitis radiology hip index
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us